

RECEIVED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GRONHOJ-LARSEN et al
 Serial No.: 09/101,825
 Filed: July 17, 1998
 For: SYNTHETIC IL-10 ANALOGUES

Art Unit: 1646
 Examiner: HAMUD, F.
 Washington, D.C.
 Atty.'s Docket: GRONHOJ-LARSEN-2
 Date: August 6, 2003

U.S. Patent and Trademark Office
 2011 South Clark Place
 Customer Window
 Crystal Plaza Two, Lobby, Room 1B03
 Arlington, Virginia 22202

Sir:

Transmitted herewith is an [XX] SUPPLEMENTAL RESPONSE, Declaration of Borbala Gesser, and Exhibit D in the above-identified application.

[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been previously asserted.

[] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

[XX] No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)	Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fee	
Total	Minus		0	x 9	\$		x18 \$
Indep.	Minus		0	x42	\$		x84 \$
First Presentation of Multiple Dependent Claim				140	\$		+280 \$
TOTAL ADDITIONAL CLAIMS FEE					\$	Total	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by

37 CFR 1.17 is calculated as shown below:

<u>Small Entity</u>	<u>Other Than Small Entity</u>
Response Filed Within	Response Filed Within
[] First - \$ 55.00	[] First - \$ 110.00
[] Second - \$205.00	[] Second - \$ 410.00
[] Third - \$465.00	[] Third - \$ 930.00
[] Fourth - \$725.00	[] Fourth - \$1450.00
[] Fifth - \$985.00	[] Fifth - \$1970.00

[] Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.


[] A check in the amount of \$ is attached (check no.).

[] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR \$1.16 and all patent processing fees under 37 CFR \$1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR \$1.18.

BROWDY AND NEIMARK, P.L.L.C.
 Attorneys for Applicant(s)
 By: *[Signature]*
 IVER P. COOPER
 Registration No. 28,005

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197



UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1646
GRONHOJ-LARSEN, et al.)
Serial No.: 09/101,825) Examiner: HAMUD, F.
Filed: July 17, 1998) Washington, D.C.
For: SYNTHETIC IL-10 ANALOGUES) August 6, 2003
) Docket No.: GRONHOJ-LARSEN=2

SUPPLEMENTAL RESPONSE

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

S i r :

It has come to our attention that page 4, lines 15-17 of the April 9, 2003 response refers to Exhibit C as "a copy of a poster relating to the involvement of cytokines in psoriasis and cancer." However, on page 4, line 1, Exhibit C is identified as a list of 25 patents reciting "disease mediated."

Accordingly, please consider the exhibit referred to at page 4, lines 15-17 to be Exhibit D, a copy of which is enclosed herewith.

Also, we take this opportunity to furnish an expert declaration which discusses the involvement of cytokines in psoriasis and cancer, referring, *inter alia*, to Exhibit D.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

IPC:ma

G:\ipc\n-q\Plou\GronhojLarsen2\PTO SupplResponse.doc